Asian Case of Metastatic Melanoma in Which a Complete Response Was Maintained after Discontinuation of Dabrafenib and Trametinib  

作　　者：Rikako Deno Atsushi Tanemura Madoka Takafuji Yuma Hanaoka Eiji Kiyohara Noriko Arase Mari Wataya-Kaneda Manabu Fujimoto Rikako Deno;Atsushi Tanemura;Madoka Takafuji;Yuma Hanaoka;Eiji Kiyohara;Noriko Arase;Mari Wataya-Kaneda;Manabu Fujimoto(Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan)

机构地区：[1]Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan

出　　处：《Journal of Cosmetics, Dermatological Sciences and Applications》2020年第2期55-58,共4页化妆品、皮肤病及应用期刊（英文）

摘　　要：A 54-year-old man diagnosed with metastatic melanoma of the right inguinal node with occult primary developed liver and bone metastases. The combination of dabrafenib plus trametinib was initiated, and a complete response (CR) was achieved 24 months after starting treatment. One month later, the target therapy was discontinued at the patient’s decision, and he has remained free from progression for 21 months since discontinuation. To the extent of our knowledge, real-world data in Asian melanoma concerning the discontinuation of dabrafenib plus trametinib after achieving CR have not been published;therefore, our case is a meaningful one for considering to cease target drugs and to rescue their financial toxicity.A 54-year-old man diagnosed with metastatic melanoma of the right inguinal node with occult primary developed liver and bone metastases. The combination of dabrafenib plus trametinib was initiated, and a complete response (CR) was achieved 24 months after starting treatment. One month later, the target therapy was discontinued at the patient’s decision, and he has remained free from progression for 21 months since discontinuation. To the extent of our knowledge, real-world data in Asian melanoma concerning the discontinuation of dabrafenib plus trametinib after achieving CR have not been published;therefore, our case is a meaningful one for considering to cease target drugs and to rescue their financial toxicity.

关 键 词：Metastatic Melanoma Dabrafenib Trametinib Complete Response DISCONTINUATION 

分 类 号：R73[医药卫生—肿瘤]